TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Electrophysiologically Guided PAcing Site Selection Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Symptomatic sinus node dysfunction~* More than 18 years old~* Signed informed consent~Exclusion Criteria:~* Less than 18 years old~* Pregnancy~* Anamnestic transient ischemic attack (TIA) or stroke~* Neoplastic or any other severe disease reducing life expectancy~* Heart surgery in the last 3 months~* Left atrial diameter \> 55mm, determined in the parasternal long-axis view (during either sinus rhythm or atrial fibrillation)~* Participation in other studies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1. IAS pacing - study group (Type: EXPERIMENTAL): Patients were first submitted to electrophysiological study to assess Delta CTos \> or \< 50 ms. Then they were randomized to interatrial septum pacing od right atrial appendage. This arm (1) includes patients with Delta CTos \>50 ms and randomized IAS pacing.~IAS Pacing -Study Group: Patients with Delta CTos \>50 ms (study group) at the electrophysiologic study and randomized Interatrial Septum Pacing
- 2. IAS pacing-control group (Type: EXPERIMENTAL): (Delta CTos\<50ms)~Patients were first submitted to electrophysiological study to assess Delta CTos \> or \< 50 ms. Then they were randomized to interatrial septum pacing od right atrial appendage. This arm (2) includes patients with Delta CTos \<50 ms and randomized IAS pacing.~IAS Pacing -Control Group: Patients with Delta CTos \<50 ms (control group) at the electrophysiologic study and randomized Interatrial Septum Pacing
- 3. RAA Pacing - study group (Type: ACTIVE_COMPARATOR): Patients were first submitted to electrophysiological study to assess Delta CTos \> or \< 50 ms. Then they were randomized to interatrial septum pacing od right atrial appendage. This arm (3) includes patients with Delta CTos \>50 ms and randomized Right Atrial Appendage pacing.~RAA Pacing -Study Group: Patients with Delta CTos \>50 ms (study group) at the electrophysiologic study and randomized Right Atrial Appendage pacing
- 4. RAA Pacing - control group (Type: ACTIVE_COMPARATOR): Patients were first submitted to electrophysiological study to assess Delta CTos \> or \< 50 ms. Then they were randomized to interatrial septum pacing od right atrial appendage. This arm (4) includes patients with Delta CTos \<50 ms and randomized Right Atrial Appendage pacing.~RAA Pacing -Control Group: Patients with Delta CTos \<50 ms (control group) at the electrophysiologic study and randomized Right Atrial Appendage pacing

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Usefulness of Medroxyprogesterone Acetate in Follicular Phase in Oocyte Donors. Undergoing Ovarian Stimulation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 18-35 years (both included)~* Regular Menses (between 25-35 days)~* Absence of physical and psychic pathologies at the time of oocyte donation~* BMI: 18-28 kg(m2 at the time of oocyte donation.~* Other criteria to comply with:~  i. With no relevant personal or family medical history ii. Signing of Informed Consent iii. From a medical point of view:~ 1. Healthy ovaries and uterus, with no organic pathology~ 2. Ovaries without polycystic aspect~ 3. Antral Follicle Count \> 12 in the sum of both ovaries~ 4. Normal Karyotype~ 5. Negative results in infectious illness screening (Hepatitis B Virus; Hepatitis C Virus, VIH Virus Syphilis)~ 6. Results within range of general analysis of hemogram, hemostasia y biochemistry.~     Exclusion Criteria:~* Any systemic or metabolic disorder which contraindicate the use of Gonadotrophines~* Medical background of Trombophlebitis or thromboembolic phenomena or Arterial Hypertension~* Severe hepatic insufficiency, cardiovascular illness~* Suspicion or evidence of malignity of mamarian glands or other hormone dependant genital organs~* Known infection of Hepatitis B Virus; Hepatitis C Virus or VIH Virus~* Known hypersensitivity to PMA or its excipients~* Any reason or cause which excluede from the oocyte donation program~* Participation in another clinical trial in the two months prior to the inclusion on this study

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- Provera (Type: EXPERIMENTAL): None
- Orgalutrán Ganirelix (GnRH antagonist) (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Exploratory Muscle Biopsy Assessment Study in Patients With Late-Onset Pompe Disease Treated With Alglucosidase Alfa

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* The participant has confirmed acid alpha-glucosidase (GAA) enzyme deficiency from any tissue source and/or confirmed GAA gene mutations and without known cardiac hypertrophy~* The participant is able to ambulate a distance without stopping and without an assistive device. Use of assistive device for community ambulation is appropriate~* The participant has a certain forced vital capacity (FVC) in upright position~* The participant, if female and of childbearing potential, must have a negative pregnancy test (urine beta-human chorionic gonadotropin \[beta-hCG\]) at baseline~Exclusion Criteria:~* The participant has had previous treatment with ERT~* The participant is wheelchair dependent~* The participant requires invasive-ventilation (non-invasive ventilation is allowed)~* The participant is participating in another clinical study using investigational treatment~* The participant cannot submit to magnetic resonance imaging (MRI) examination because of a formal contraindication such as a pacemaker, implanted ferromagnetic metals, etc~* The participant, in the opinion of the Investigator, is unable to adhere to the requirements of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Alglucosidase Alfa (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tacrolimus Versus Hydrocortisone in Atopic Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients~* 2-16 years old~* diagnosed with Atopic Dermatitis according to Hanifin and Rajka criteria~Exclusion Criteria:~* patients with serious skin disorder other than Atopic Dermatitis~* patients taking systemic corticosteroids or anti-inflammatory medications.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- Tacrolimus group (Type: ACTIVE_COMPARATOR): 100 patients treated by thin layer of 0.03% topical tacrolimus ointment on the affected areas twice daily for 4 months.
- Hydrocortisone group (Type: ACTIVE_COMPARATOR): 100 patients treated by thin layer of 1% hydrocortisone cream on the affected areas twice daily for 4 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of Different Analgesic Options in Kidney Stone Pain Management

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age \>=18 years and \< 65 years~* Acute onset, one side flank or loin pain, with or without radiation to groin or genital areas.~* Pain intensity on NRS more than or equal to 4. (Moderate to Severe Pain)~* Diagnosis confirmed by non contrast CT KUB within the ED visit.~Exclusion Criteria:~* Traumatic flank pain~* Pregnancy~* Known renal failure or impairment~* Known allergy to morphine, diclofenac or paracetamol~* Bronchial asthma~* Previously enrolled in the study.~* Use of any analgesia in last 6 hour.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Diclofenac and Placebos (Type: EXPERIMENTAL): Participants in this group will receive a Diclofenac 75 mg intramuscular injection, and two placebo saline solutions intravenously.
- Morphine and Placebos (Type: ACTIVE_COMPARATOR): Participants in this group will receive Morphine 0.1 mg/kg intravenously, along with an additional intravenous placebo and an intramuscular placebo injection.
- Paracetamol and Placebos (Type: ACTIVE_COMPARATOR): participants in this group will receive intravenous Paracetamol 1 gm solution, along with an additional intravenous placebo and an intramuscular placebo injection.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase I Clinical Study to Investigate the Pharmacokinetics and Safety/Tolerability of DA-7218 in Healthy Male Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male Korean 19-45 years~* Body weight:55-90kg, BMI:18.0-27.0~Exclusion Criteria:~* Present condition or history of any clinically significant disease~* Clinical evidence or history of GI disease or history of GI surgery~* History of hypersensitivities, including drug allergies~* AST (SGOT) or ALT (SGPT) \> 1.5 times the upper normal limit~* Systolic blood pressure : \<100 mmHg or \>160 mmHg~* Diastolic blood pressure : \<60 mmHg or \>100 mmHg~* Drug abuse within 2 months, or a positive reaction to an abusive drug or cotinine~* Taken any ETC or herbal supplement within 2 weeks or any OTC or vitamin supplement within 1 week~* Participation in and administration of IP of another clinical trial within 2 months~* Donation of whole blood within 2 months, or blood components within 1 month, or receipt of blood transfusion within 1 month~* Consumption of more than 21 units of alcohol/week or inability to abstain from drinking during the study period~* Smoking within 3 months~* Taking caffeine- or grapefruit-containing products within 3 days~* Plan to be pregnant, or not to use an appropriate method of contraception

- Gender: MALE
- Minimum Age: 19 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- [Group 1] DA-7218 (Type: EXPERIMENTAL): 200mg, By mouth or orally (PO) \& intravenous(IV) administration
- [Group 1] Placebo (Type: PLACEBO_COMPARATOR): Placebo, By mouth or orally (PO) \& intravenous(IV) administration
- [Group 2] DA-7218 (Type: EXPERIMENTAL): 400mg, By mouth or orally (PO) administration
- [Group 2] Placebo (Type: PLACEBO_COMPARATOR): Placebo, By mouth or orally (PO) administration
- [Group 3] DA-7218 (Type: EXPERIMENTAL): 600mg, By mouth or orally (PO) administration
- [Group 3] Placebo (Type: PLACEBO_COMPARATOR): Placebo, By mouth or orally (PO) administration

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male and females, ≥18 to ≤77 years old, with type 2 diabetes mellitus~* Subjects must have central laboratory pre-randomization A1C ≥7.0 and ≤ 10.0%~* C-peptide ≥ 1.0 ng/mL (0.34 nmol/L)~* Body Mass Index ≤ 45 kg/m²~* Must be able to perform self monitoring of blood glucose~Exclusion Criteria:~* aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) \>3\* upper limit of normal (ULN)~* Serum Total bilirubin \>2 mg/dL (34.2 µmol/L)~* Creatinine kinase \>3\* ULN~* Serum creatinine ≥1.50 mg/dL (133 µmol/L) for male subjects, ≥1.40 mg/dL (124 µmol/L) for female subjects~* Currently unstable or serious cardiovascular, renal, hepatic, hematological, oncological, endocrine, psychiatric, or rheumatic diseases

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 77 Years
- Healthy Volunteers: f

Study Arms:
- Dapagliflozin 1 mg (Type: EXPERIMENTAL): Dapagliflozin: 1 mg
- Dapagliflozin 2.5 mg (Type: EXPERIMENTAL): Dapagliflozin: 2.5 mg
- Dapagliflozin 5 mg (Type: EXPERIMENTAL): Dapagliflozin: 5 mg
- Placebo (Type: PLACEBO_COMPARATOR): Placebo: 0 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Clinical Trial Comparing 4RIF vs. 9INH for LTBI Treatment-effectiveness

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult (age 18 years and older) with documented positive TST (or in the absence of TST, a documented positive QFT) and prescribed 9 months of Isoniazid for LTBI, following authoritative recommendations.~Exclusion Criteria:~* Patients who were contacts of TB cases known to be resistant to Isoniazid, Rifampin, or both.~* Known HIV-infected individuals on anti-retroviral agents whose efficacy would be substantially reduced by Rifampin, unless therapy can safely be changed to agents not affected by Rifampin.~* Pregnant women - Rifampin and Isoniazid are considered safe in pregnancy but therapy is usually deferred until 2-3 months post-partum to avoid fetal risk and the potential for increased hepato-toxicity immediately post partum.~* Patients on any medication with clinically important drug interactions with Isoniazid or Rifampin, which their physician believes would make either arm contra-indicated.~* Patients with a history of allergy/hypersensitivity to Isoniazid or to Rifampin, Rifabutin or Rifapentine.~* Patients with active TB. Patients initially suspected to have active TB can be randomized once this has been excluded.~* Patients who have already started LTBI therapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Isoniazid (Type: ACTIVE_COMPARATOR): The dosage of the medication is determined according to the weight of the subject. The dose is once per day, in pill format, for a total daily dose of 300mg if subject weighs ≥ 42 kg, otherwise 200 mg. Total duration of treatment is for 9 months.
- Rifampin (Type: ACTIVE_COMPARATOR): The dosage of the medication is determined according to the weight of the subject. The dose is once per day, in pill format, for a total daily dose of 600 mg if the subject weighs ≥ 50 kg, 450 mg if the subject weighs ≥ 36 kg and \< 50 kg, otherwise 300 mg for those weighing \< 36 kg. Total duration of treatment is for 4 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study of Cognitive Behavioral Therapy for Anxiety and Bipolar I Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women age 18-65~* DSM-IV diagnosis of bipolar I disorder and at least one of three additional anxiety disorders:~generalized anxiety disorder, panic disorder, or social phobia.~* HAM-D-17 score \<16 (i.e. depressive symptoms)~* YMRS score \< 12 (i.e. no or very low manic symptoms)~* Current, stabilized (\> 3 months) pharmacotherapy treatment under the care of a psychiatrist consisting of optimized, stable maintenance pharmacotherapy at maximum tolerated dosages according to Texas Implementation of Medication Algorithm.~Exclusion Criteria:~* Active suicidality (HAM-D-17 suicide item #3 score \> 3) in the past 2 months. Potential participants scoring 3 or higher on the HAM-D-17 suicide item will be immediately evaluated by the PI and Sponsor and referred to a higher level of care if clinically indicated.~* DSM-IV bipolar I disorder subtype rapid cycling~* DSM-IV manic or mixed episode in the past 2 months~* DSM-IV major depressive episode in the past 2 months~* Psychotropic medication not in accordance with the revised Texas Implementation of Medication Algorithm~* Current Pregnancy~* Medical illness or non-psychiatric medical treatment that would likely interfere with study participation.~* Neurologic disorder, previous ECT, or history of head trauma (i.e. known structural brain lesion)~* Current or past history of selected DSM-IV Axis I disorders other than bipolar disorder including: organic mental disorder, substance abuse within the past 12 months and/or history of substance abuse for \> 1 year; current substance dependence (including alcohol), as assessed by the Structured Clinical Interview for DSM-IV-TR, Substance Use Disorders (Section E); schizophrenia, delusional disorder, psychotic disorders not otherwise specified, obsessive compulsive disorder and posttraumatic stress disorder (due to low prevalence of \~6.5% each).~* Concurrent psychotherapy other than cognitive-behavioral therapy as provided in this study (to rule out other uncontrolled effects of concurrent psychotherapies)~* Presence of metallic implants that would interfere with safety during fMRI scanning (i.e. cardiac pacemaker, metal plates, etc.)~* Claustrophobia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Treatment as usual plus UP CBT (Type: EXPERIMENTAL): Existing psychiatrist-administered psychopharmacotherapy plus weekly transdiagnostic CBT
- Treatment as usual (Type: ACTIVE_COMPARATOR): Existing psychiatrist-administered psychopharmacotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Relative Bioavailability Study of Selpercatinib (LY3527723) in Healthy Participants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, and vital signs~* Body mass index (BMI) within the range 18.0 to 35.0 kilograms per meter squared (kg/m²)~Exclusion Criteria:~* Have a history of allergic reactions to medications or food products~* Have a clinically significant abnormality of blood pressure and/or pulse rate as determined by the investigator~* Clinically significant abnormalities on ECG as determined by the investigator or prolongation of the QTcB or QTcF \>450 msec at screening~* Have clinically significant active cardiovascular disease or history of myocardial infarction within 6 months prior to the planned start of selpercatinib~* Have a history or presence of cardiovascular, respiratory, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the investigational product; or of interfering with the interpretation of data. Appendectomy, splenectomy, and cholecystectomy are considered as acceptable~* Use of H2 blockers, proton pump inhibitors, and other drugs that affect selpercatinib exposure within 7 days of screening~* Are intending to use over-the-counter or prescription medication, including dietary supplements, within 14 days prior to dosing and until study discharge (apart from occasional acetaminophen (≤2 g/24 hours), hormonal contraception, or hormone replacement therapy)

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Selpercatinib (Formulation 1) (Type: EXPERIMENTAL): Selpercatinib (formulation 1) given orally on days 1, 8 or 15.
- Selpercatinib (Formulation 2) (Type: EXPERIMENTAL): Selpercatinib (formulation 2) given orally on days 1, 8 or 15.
- Selpercatinib (Formulation 3) (Type: EXPERIMENTAL): Selpercatinib (formulation 3) given orally on days 1, 8 or 15.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bronchiectasis and Long Term Azithromycin Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged 18 ≥ years~* Bronchiectasis diagnosed by plain bronchography or high resolution computer tomography.~* Minimal 3 lower respiratory tract infections (LRTI) treated with oral/intravenous (IV) antibiotics in the year preceding the study inclusion.~* The presence of chronic respiratory symptoms such as cough, dyspnoea, expectoration of sputum.~* At least one positive sputum culture in the preceding year.~* Informed consent~Exclusion Criteria:~* Previous ( ≥ 4 weeks) prolonged macrolide therapy.~* Pregnant or lactating women.~* Allergy to macrolides.~* Intolerance to macrolides.~* Liver disease (alanine transaminase and/or aspartate transaminase levels 2 or more times the upper limit of normal).~* Use of antibiotics within 14 days of screening.~* Use of oral or IV corticosteroids (≥ 30 mg prednisolone/daily) within 30 days of screening.~* Other research medication started 2 months prior to inclusion.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Azithromycin treatment 1 (Type: ACTIVE_COMPARATOR): None
- Placebo 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete